Prothrombin complex concentrates (PCC), licensed for the treatment of hemophilia B, are known to carry a significant risk of thromboembolic complications. Although the reasons for thrombogenicity are not completely understood, several manufacturers have developed purified factor IX concentrates that contain negligible amounts of the other vitamin K-dependent factors. To evaluate whether or not ...

The concentration of fibronectin was assessed in a variety of coagulation factor preparations. Highest concentrations of fibronectin were found in the intermediate purity factor VIII concentrates. Significant amounts were found in cryoprecipitate but high purity factor VIII concentrates contained only small amounts. For practical purposes factor IX concentrates contained no fibronectin. Qualita...

Coagulation factor replacement can effectively treat or prevent most hemophilia complications, but it is expensive. Although published data describe how to achieve therapeutic goals through cost-effective selection and dosing of replacement products, criteria are not universally known or followed. A review of our institution’s experience revealed overdosing of coagulation factors in the majorit...

Unexpectedly elevated INR values are commonly encountered in clinical practice. In the absence of bleeding, such values may be treated with either simple warfarin withdrawal or the administration of low doses of oral vitamin K. Oral vitamin K will more rapidly return the INR to the therapeutic reference interval; however, its impact on bleeding is unknown. If the INR is in excess of 10, most ex...

BACKGROUND Circumcision in hemophiliacs is a delicate surgery because of bleeding risks that could be avoided by adequate substitution of coagulation factor. This practice is very challenging in countries where anti hemophilic treatment is inaccessible. The study aimed to evaluate a circumcision protocol in hemophilia A using low quantities of factor concentrates. METHODS This prospective stu...

background: factor vii concentrates are used in patients with congenital or acquired factor vii deficiency or treatment of hemophilia patients with inhibitors. in this research, immunoaffinity chromatography was used to purify factor vii from prothrombin complex (prothrombin-proconvertin-stuart factor-antihemophilic factor b or ppsb) which contains coagulation factors ii, vii, ix and x. the aim...

PURPOSE OF REVIEW The purpose of this review is to highlight the use of tranexamic acid, point-of-care testing, algorithm-based treatment of trauma-associated coagulopathy with factor concentrates to reduce blood loss and transfusion requirements in order to improve outcome. In addition, the management of patients on new oral anticoagulants, drugs with renewed interest and the tolerance of rela...